Dr. Richard Isaacson, United States
January 31, 2022
What makes the Quality of Life endpoint useful in #AlzheimersDisease clinical trials? Watch Dr. Richard Isaacson discuss the QoL-AD.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.